Define AD and discuss disease-related events, etiology and epidemiology of AD. Investigate the global and regional markets for the drugs and diagnostic technologies for the treatment of Alzheimer’s disease (AD). Analyze market dynamics for the interpretation and forecasting of the sales of AD drugs and diagnostics. Evaluate the developments in the global market for AD therapeutics and diagnostics.
The global market for AD therapeutics and diagnostics by region should reach over $6.2 billion by 2020 from $4.4 billion in 2015, a compound annual growth rate (CAGR) of 7.1% from 2015 to 2020. The North American market should reach over $2.9 billion by 2020 from 2.2 billion in 2015, at a CAGR of 5.3% from 2015 to 2020. The Asia-Pacific market should reach over $2.6 billion by 2020 from $1.6 billion in 2015, at a CAGR of 10.7% from 2015 to 2020.
The aim of this report is to investigate the global and regional markets for the drugs and diagnostic technologies used for the treatment and diagnostic evaluation of Alzheimer’s disease (AD). This report defines AD and discusses the disease-related events, etiology and epidemiology of AD by providing information on prevalence and incidence rates, diagnostic tools and equipment, and by introducing important scientific and technological frameworks to better grasp the developments in the global market for AD therapeutics and diagnostics.
Products that are currently available for the diagnosis and treatment of AD are introduced and evaluated according to the report’s methodology. The report also highlights promising new drug candidates and diagnostic imaging agents.
Key drivers and restraints, as well as major opportunities versus threats for the future growth and direction of the individual and global markets, are identified and addressed.
The classification and comparison of distinct segments of AD drugs and diagnostic imaging products are provided in the report, and current and future developments are highlighted for each existing and novel market segment. Current market dynamics and characteristics are analyzed for the interpretation and forecasting of the sales of AD drugs and diagnostics. Product revenues are broken down by regional and country markets. Sales figures are estimated for the global and regional markets for the period between 2015 and 2020.
REASONS FOR DOING THE STUDY
Alzheimer’s disease cannot be prevented, cured or slowed, and it is a rapidly growing and serious health problem, affecting more than 17 million worldwide. Therapies for AD provide temporary and modest improvements in the well-being of individuals, and none of the approved drugs can modify the course of the disease progression. The mmense size of the affected population and lack of appropriate and effective treatment offers a tremendous commercial opportunity.
The understanding of the underlying reasons and mechanisms involved in AD is very limited. Drug developers have been failing to demonstrate meaningful clinical benefits of treatment for a myriad of investigational compounds due to stringent regulations.
High drug attrition rates and long drug approval times have driven pharmaceutical companies and technology ventures closer to each for collaboration. Specifically, diagnostic technology companies are rigorously trying to bring about effective biomarker technologies to assist and enhance the drug development process for prospective drug candidates. Regulatory bodies are highly supportive of the use of diagnostic technologies in order to improve drug attrition rates.
Despite the recurring failures in the development of novel therapies for AD, the global markets are demanding new and more effective, disease attenuating treatments, with first-in-class approvals. This expectation and the increasing incidence of AD associated with the aging population are driving the market.
Our reports have been used by over 10K customers, including:
Report Scope The report details the antiemetic drug market.The analysis highlights current and future market potential for antiemetic drug and presents a detailed review of pipeline drugs, blockbuster drugs, and challenges to market growth. The report also examines disease burden, regulatory environment, novel technologies,...
576 pages •
By IQ4I Research & Consultancy Pvt. Ltd
• Jul 2018
Over the past 50 years nuclear medicine field has displayed a strong link between investments in chemistry and development of radionuclides and radio-labeled compounds which has impacted the healthcare practice. Nuclear medicine comprises diagnostic and therapeutic techniques that use radioisotopes for applications...
The global influenza vaccines market is anticipated to exceed US$ 5.8 Billion mark by 2024, and is presenting ample opportunities to the industry’s players. Influenza viruses are considered as a major cause of morbidity and mortality worldwide. The vast population base together with significantly low vaccination coverage in emerging markets,...
Pediatric Vaccine Market is projected to exceed US$ 48 Billion by the year 2024. Increasing government and non-government funding for the development of new vaccines, along with raising awareness about the benefits of vaccination, is certainly expected to positively drive the market growth in the coming years. In order...
Adult Vaccine Market is projected to reach US$ 22 Billion by the year 2024. Vaccination can help prevent certain diseases in all the people. Nearly all countries across the globe have introduced a well-organized National immunization Programs in their vaccination schedule to overcome the outbreak of vaccine-preventable...
The Global Antibiotics Market is expected to reach USD XX million by 2022 from USD XX million in 2016, at a CAGR of XX%. Antibiotic resistance accounts for 50,000 deaths per year in the US and Europe alone. Routine surgeries and minor infections might become life threatening if novel antibiotics are not developed. In spite of microbial resistance...